Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: J Neurooncol

Search In Journal Title:

Abbravation: Journal of Neuro-Oncology

Search In Journal Abbravation:

Publisher

Kluwer Academic Publishers-Plenum Publishers

Search In Publisher:

ISSN

1573-7373

Search In ISSN:
Search In Title Of Papers:

Retrospective analysis of the efficacy and tolerab

Authors: Herbert B Newton Jennifer Dalton Samuel Goldlust Dennis Pearl
Publish Date: 2007/04/13
Volume: 84, Issue: 3, Pages: 293-296
PDF Link

Abstract

Seizures are a common complication of metastatic brain tumors MBT affecting approximately 27–50 of all patients during the course of their illness Treatment of tumorinduced seizures is often inadequate with traditional antiepileptic drugs AED due to a variety of factors including activation of glutamatergic NMDA receptors alterations of neuronal input pathways and tumor growth Levetiracetam LEV is a 2nd generation nonenzyme inducing AED with a novel mechanism of action binding to neuronal synaptic vesicle protein SV2A that has been previously shown to reduce seizure activity in patients with primary brain tumors Due to its unique mechanism of action it has been postulated that LEV may also be effective in controlling seizures from MBT A retrospective chart review was performed of all NeuroOncology Center patients with MBT who had received LEV for seizure control Thirteen patients were reviewed with a median age of 551 years range 34–70 Six patients had breast cancer five had lung cancer and two had melanoma LEV was used as an addon AED in seven patients 54 and as monotherapy in six patients 46 with a median dose of 1000 mg/day range 500–3000 The baseline median seizure frequency was one ictal event every other day After the addition of LEV the median seizure frequency was reduced to 0 per week The seizure frequency was reduced to less than 50 of the preLEV baseline in 100 of patients P = 00002 Sign test with 10 patients 77 confidence interval 46–95 noting complete seizure control The most common adverse event was somnolence and headache noted in 3 of 13 patients 23 LEV was very effective and well tolerated in MBT patients with seizures and should be considered for addon therapy or as a substitute AED for monotherapy


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma
  2. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells
  3. Origins and clinical implications of the brain tumor stem cell hypothesis
  4. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design
  5. All- trans retinoic acid inhibits craniopharyngioma cell growth: study on an explant cell model
  6. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
  7. Quality of radiosurgery for single brain metastases with respect to treatment technology: a matched-pair analysis
  8. Phase II trial of temozolomide in children with recurrent high-grade glioma
  9. Management of patients with recurrence of diffuse low grade glioma
  10. Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms
  11. Cognitive outcome as part and parcel of clinical outcome in brain tumor surgery
  12. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types
  13. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma
  14. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
  15. A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors
  16. Extraneural metastatic medulloblastoma in an adult
  17. Incidence of craniopharyngioma in Denmark ( n = 189) and estimated world incidence of craniopharyngioma in children and adults
  18. Application of diffusion-weighted magnetic resonance imaging to predict the intracranial metastatic tumor response to gamma knife radiosurgery
  19. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades
  20. Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas
  21. Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma
  22. Multiple paraneoplastic diseases occurring in the same patient after thymomectomy
  23. Age alone is not a predictor for survival in glioblastoma
  24. Clear cell Meningioma, an uncommon variant of meningioma: a clinicopathologic study of nine cases
  25. Weight of epilepsy in brain tumor patients
  26. Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH–cortisol and renin–angiotensin–aldosterone
  27. PI3Kinase signaling in glioblastoma
  28. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma
  29. Gamma Knife radiosurgery for brainstem metastases: the UCSF experience
  30. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma
  31. Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03
  32. Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma
  33. Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults
  34. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells
  35. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors
  36. Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma
  37. Leukoencephalopathy in long term brain metastases survivors treated with radiosurgery
  38. Variation of O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma
  39. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
  40. Rho GTPases in primary brain tumor malignancy and invasion
  41. Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma
  42. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of ‘hook effect’
  43. Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma
  44. Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease
  45. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
  46. Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme
  47. Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal
  48. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas
  49. Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas
  50. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics
  51. The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma
  52. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen
  53. Images in neuro oncology: Primary extraaxial cerebellopontine angle ependymoma
  54. The peabody picture vocabulary test as a pre-screening tool for global cognitive functioning in childhood brain tumor survivors
  55. Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma
  56. Skull base meningiomas: neurological outcome after microsurgical resection
  57. Stereotactic biopsy of brainstem lesions: 21 years experiences of a single center
  58. Caloric restriction reduces edema and prolongs survival in a mouse glioma model
  59. Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study
  60. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors
  61. The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis

Search Result: